APOB and metabolic syndrome: The LOWESS curves of the differences between the measured serum apoB and the estimated apoB for all subjects, patients with diabetes (n = 9,084, 11.6%), patients with atherogenic dyslipidemia (n = 4,763, 6.1%), and patients taking lipid-lowering agents (n = 2,650, 3.4%) are shown in Figs. 3A and 3B.